<DOC>
	<DOCNO>NCT00458887</DOCNO>
	<brief_summary>RATIONALE : New way find hearing loss treatment chemotherapy may improve ability plan cancer treatment may help patient live comfortably . PURPOSE : This clinical trial assess ear damage young cancer patient treat cisplatin .</brief_summary>
	<brief_title>Assessing Ear Damage Young Cancer Patients Treated With Cisplatin</brief_title>
	<detailed_description>OBJECTIVES : - Determine optimal criterion determination ototoxicity young cancer patient treat cisplatin . - Determine feasibility include ultrahigh frequency evoke otoacoustic emission test adjunctive measure ototoxicity . - Determine feasibility necessity central review audiometry data . OUTLINE : This multicenter , prospective , cohort study . Patients undergo hearing test ( conventional , otoscopy , ultrahigh frequency , otoacoustic emission test ) first course plan cisplatin , subsequent course cisplatin , 4 week last dose cisplatin . Patients schedule receive hematopoietic progenitor stem cell transplantation undergo hear test transplantation 4 week transplantation . PROJECTED ACCRUAL : A total 282 patient accrue study .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Planning undergo treatment cisplatincontaining therapeutic regimen cancer Treatment need COG therapeutic study Planning enroll clinical trial ACCL0431 PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior cisplatin</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ototoxicity</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>